NVAX NOVAVAX INC
FY2025 10-K
NOVAVAX INC (NVAX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: development and commercialization of vaccines using proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant platform
- • New emphasized partnerships: non-exclusive Matrix-M™ licenses to Pfizer (Jan 2026) and expanded Sanofi agreement for pandemic influenza and COVID-19 combination vaccines
Management Discussion & Analysis
- • Revenue $1.12B in 2025, up $441.3M YoY, driven by $685M product sales (+$471.8M) and $438.4M licensing (-$30.5M)
- • Operating expenses $670.7M in 2025 vs $931.1M in 2024; cost of sales 10.7% of product sales vs 95.1% in 2024; R&D $342.3M vs $391.2M; SG&A $157.5M vs $337.2M
Risk Factors
- • Regulatory risk: Uncertainty in revenue recognition from licensing agreements under ASC 606 requiring judgment on variable consideration and revenue timing
- • Macroeconomic threat: Exposure to fluctuating interest rates with 4.625% Convertible Senior Notes and variable term loans tied to Term SOFR plus 5.00%
Get deeper insights on NOVAVAX INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.